NYSE:ABBV Stock Report
Market Cap $410.09B
$232.03
+3.27%
+$7.34 today
Market Cap
$410.09B
P/E Ratio
Discount23.20
Sector: 34.08
EPS
$2.71
Volume
4.2M
Year High
$244.81
Year Low
$164.39
50-Day MA
Above$224.13
200-Day MA
Above$212.09
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
AbbVie Inc. (ABBV) is currently trading at $232.03 with a market consensus rating of Buy, reflecting broad analyst confidence in the company's growth prospects. The stock has a moderate upside potential of approximately 10.4% based on a consensus price target of $256.15. Recent analyst actions show stability with notable upgrades such as HSBC's move from Hold to Buy, balanced by Wolfe Research's downgrade from Outperform to Peer Perform, indicating some caution but no significant shift in overall sentiment. The company is actively investing in its future, notably with a $380 million commitment to expand its active pharmaceutical ingredient (API) manufacturing capabilities in North Chicago, incorporating advanced AI technologies to support next-generation neuroscience and obesity drugs. This expansion is expected to enhance operational efficiency and supply chain resilience while creating 300 new jobs. Key developments include AbbVie's strategic diversification beyond its legacy blockbuster Humira, which lost U.S. patent exclusivity in 2023. Growth drivers now center on immunology products like Skyrizi and Rinvoq, which are expected to deliver significant sales growth. The neuroscience portfolio, including Vraylar and Botox Therapeutic, along with the oncology segment featuring Imbruvica and Venclexta, contribute to a balanced revenue base. The company’s robust R&D pipeline, including early-stage clinical trials such as ABBV-547, offers potential for future revenue streams. Financially, AbbVie benefits from strong cash flow and margin expansion, enabling continued investment in innovation and manufacturing. On the risk side, AbbVie faces execution challenges related to scaling new manufacturing technologies and potential competitive pressures from biosimilars and novel therapies in immunology and oncology. Regulatory risks persist, including pricing pressures and policy changes that could impact profitability. Macro factors such as economic slowdowns and currency volatility add further uncertainty. Valuation remains a concern as the stock trades at a premium, leaving limited room for error if growth or margins falter. Overall, the company’s strong strategic positioning and investment in growth areas balance these risks. Looking forward, AbbVie’s focus on expanding manufacturing capacity, advancing its clinical pipeline, and capitalizing on growth in specialty pharmaceuticals positions it well for sustained growth. Continued monitoring of competitive dynamics and regulatory developments will be critical. The stable to improving analyst sentiment and ongoing capital investments support a positive outlook for the stock over the near to medium term.
Price Target
39 analysts$256.15
Range: $223.00
→
$299.00
Upside Potential
+10.4%
From current price
Consensus Rating
Rating Distribution
Buy
Hold
Sell
AbbVie's growth outlook is underpinned by several significant catalysts. The company's $380 million investment in two new API manufacturing facilities at its North Chicago campus is a major strategic move, integrating advanced manufacturing technologies and AI to support production of next-generation neuroscience and obesity drugs. This expansion not only enhances manufacturing capacity and operational efficiency but also strengthens supply chain resilience and creates approximately 300 new jobs, signaling strong commitment to innovation and domestic production. Additionally, AbbVie's diversified product portfolio beyond Humira, with strong growth expected from immunology drugs like Skyrizi and Rinvoq, as well as expanding neuroscience and oncology franchises, provides multiple revenue streams. The advancement of early-stage clinical trials, such as ABBV-547, offers potential for future therapeutic breakthroughs and revenue growth. Analyst sentiment remains broadly positive, with a consensus Buy rating and a price target upside of over 10%, supported by recent upgrades and stable overweight/outperform ratings from major firms. Industry trends favoring specialty pharmaceuticals and biologics, combined with AbbVie's robust R&D and capital investment plans, further bolster the company's growth prospects.
AbbVie faces several notable risks that could impact its growth trajectory. Execution risk is prominent as the company scales up new manufacturing facilities and integrates advanced technologies, which could face delays or cost overruns. Competitive pressures remain intense, particularly in immunology and oncology, where biosimilars and novel therapies threaten market share. Dependence on key products like Skyrizi and Rinvoq means that any clinical setbacks, regulatory hurdles, or slower market adoption could materially affect revenues. Regulatory risks persist, including pricing pressures and potential policy changes that could constrain profitability, despite recent agreements to lower prices in exchange for tariff exemptions. Macro-economic factors such as economic slowdowns, interest rate fluctuations, and currency volatility add further uncertainty. Valuation concerns are also significant, as AbbVie's shares trade at a premium relative to intrinsic value estimates, limiting downside protection if growth disappoints. While no major controversies have emerged recently, ongoing competitive and pipeline uncertainties require vigilant execution and strategic management.
Explore similar companies in the Healthcare sector